Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
収録刊行物
-
- The Lancet Oncology
-
The Lancet Oncology 22 (7), 931-945, 2021-07
Elsevier BV